A 2025 UC San Diego observational study of more than 6,800 colon cancer patients reported that 15% of patients using GLP-1 receptor agonist medications (such as Ozempic or Wegovy) died within five years versus 37% of non-users, after adjustment for age, cancer severity, and other medical conditions; the association was strongest in patients with body mass index (BMI) âĨ35.
November 11, 2025
medium
statistical
Summary of the study's main adjusted five-year mortality comparison and subgroup effect by obesity level.
Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand name Mounjaro), are medications used to treat type 2 diabetes and obesity.
October 10, 2025
high
temporal
Baseline description of the drug class and common brand examples.
GLP-1 receptor agonist medications (examples include semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro, and other agents such as Zepbound) mimic the gut hormone glucagon-like peptide-1 (GLP-1) and act by slowing digestion, reducing appetite, and helping to control blood sugar after meals.
January 01, 2025
high
descriptive
Mechanism of action and metabolic effects of GLP-1 receptor agonist medications used for weight loss and glycemic control.
GLP-1 receptor agonist medications (examples include semaglutide, liraglutide, and tirzepatide) mimic endogenous hormones that help regulate blood sugar and appetite.
high
general
Pharmacologic description of the GLP-1 receptor agonist drug class.
GLP-1 drugs, including semaglutide formulations marketed as Ozempic and Wegovy, are used both for weight loss and for treatment of type 2 diabetes.
high
descriptive
Therapeutic uses of GLP-1 receptor agonist medications.
Wegovy and Ozempic are weight-loss drugs marketed by Novo Nordisk that belong to the GLP-1 class of medications.
high
definition
Identifies the therapeutic use, manufacturer, and pharmacological class of the drugs mentioned in the article.